Survival in SSC PAH has improved. Morrisroe et al (1) examined 132 patients in a cohort study between 2007 and 2015. PAH was defined by right heart catheterization and no patients had interstitial lung disease (ILD). A total of 68.9% of patients had limited cutaneous SSC; 58.3% survived with a median survival time of 4.4 years (previous survival rates were approximately 50% 2-year survival). Patients treated with combination therapy for their PAH survived longer than those using monotherapy-approximately 10% greater survival on combination therapy versus monotherapy (p = 0.0002). A well-controlled study in SSC PAH is needed, although such trials are already ongoing for PAH overall (generally this includes 20% to 25% connective tissue disease patients, of whom 70%-80% have SSc). Although survival in SSc-PAH is improved, survival in scleroderma PAH leaves room for further improvement. It is still only approximately 60% four plus year survival. Paraffin baths Gregory and colleagues (2) completed a small, singleblind, randomized controlled trial of paraffin baths to examine hand function in SSc. In 36 patients, they examined the use of paraffin versus no paraffin baths on a background of regular hand exercises. The hand mobility scale in scleroderma (HAMIS), the scleroderma HAQ-DI and Cochin hand score were the outcome measures. There was no difference between control and experimental therapies for any of these outcomes.